Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $360.3 million.

  • Axsome Therapeutics' Total Current Liabilities rose 8364.62% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.3 million, marking a year-over-year increase of 8364.62%. This contributed to the annual value of $230.1 million for FY2024, which is 6571.65% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Total Current Liabilities stood at $360.3 million, which was up 8364.62% from $342.1 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Total Current Liabilities peaked at $360.3 million during Q3 2025, and registered a low of $24.5 million during Q1 2022.
  • Its 4-year average for Total Current Liabilities is $159.8 million, with a median of $138.9 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 30999.48% in 2023, then surged by 4311.49% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Total Current Liabilities stood at $96.6 million in 2022, then soared by 43.8% to $138.9 million in 2023, then soared by 65.72% to $230.1 million in 2024, then soared by 56.58% to $360.3 million in 2025.
  • Its last three reported values are $360.3 million in Q3 2025, $342.1 million for Q2 2025, and $243.9 million during Q1 2025.